All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Blogs » BioWorld Perspectives » An inconvenient truth

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

An inconvenient truth

Nov. 10, 2015
By Mari Serebrov
No Comments

JaymiToo often, drugmakers confuse convenience with quality of life, investing untold R&D resources in devising longer-acting formulations and then calling it “innovation.” The only innovation is in how it fends off competition by extending their patent protection.

Such “advances” ignore what truly matters to patients. For cancer patients who are so weakened by drugs that they don’t have the strength to roll over in bed or get out of a chair, taking a medicine once a day or twice a day makes no difference. All they want is their life back. They want to have the strength to hug their children, to be able to feel the sun warming their skin, to take just one small step without the fear of falling. Mere survival is not enough. They want to live.

Four years ago, I introduced you to my niece Jaymi, who was battling Hodgkins. Jaymi died Sunday. She was 27. After 13 years of fighting Hodgkins and enduring three transplants, full-body radiation, and round after round of chemo and steroid treatments, Jaymi, pictured here with her husband and daughter, was declared cancer-free a few weeks ago. She died of a sudden brain bleed, a result of her extensive drug regimen. She survived the cancer, but she couldn’t survive the drugs that were used to drive it away.

Jaymi’s latest ordeal, her third transplant, started in May, just a few days after she graduated with highest honors with her MBA in accounting. For as long as she still had the strength to press the keys on her computer, she wrote a blog, Something Beautiful, detailing her experience. She intended the blog to be inspirational and meaningful. It is – just not in the way she had imagined. The deterioration of her life as the drugs wreaked havoc on her body is a hard, yet revealing, read.

“My hands can barely move. And this intense, impending sadness is settling over me, and I want to stop right now,” she said in her last post to Something Beautiful. “But this is why I am writing this post. To get it out. To let someone know. Because it is real. I am beyond broken. I have contemplated suicide, laid in bed and willed myself to cease existing, felt like I would literally break into pieces of sadness and sickness because my brain is still here, and my body is so far gone and there is absolutely nothing I can do about it.

“The past couple weeks have been nothing but decline and bad news, and I am at my wit's end. I have never been in this place before. I no longer fear death. I can see the beauty of it. I have never, ever reached such a point in my life. I wish for it. I wish I had never had this transplant. I wish I had taken the few years I had left and lived my life rather than let my daughter become my caretaker, my husband my lifeline who must do every small task set before me other than put food in my mouth. And that may come next.”

More than a month after that heart-wrenching post, Jaymi got the news that the cancer was gone. She had asked for an antidepressant and was recognizing each little step forward as a life-changing victory. “A few weeks ago, I could literally barely move, and now I can climb up onto a curb [with a walker]. Yes, it is a small step, literally and figuratively, but it is a step. And I will continue to revel in what seem to be small victories, because they will eventually win the war that leads me back to myself,” she said in a Facebook post last month.

“All-in-all, life is far from perfect. I am nowhere near who or what I want to be. But it is getting better every day, and it will continue to do so as long as I am willing to get up and work for it,” she wrote.

Unfortunately, her can-do attitude that had gotten her over so many hurdles wasn’t enough to fight the final blow.

As I try to make sense of the last chapter of Jaymi’s life, I wonder how much further we would be in our fight against cancer and other traumatic diseases if drugmakers understood the difference between convenience and true quality of life. Of survival vs. living. I also wonder how many more real cures we would have today if they had invested their R&D resources in true innovation rather than in patent-extending convenience formulations.

For all the Jaymis who are fighting to live, let’s get our priorities right.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing